Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Taysha Gene Therapies's 1-Year ROIIC % for the quarter that ended in Jun. 2026 was 484.87%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Taysha Gene Therapies's 1-Year ROIIC % or its related term are showing as below:
TSHA's 1-Year ROIIC % is ranked better than 89.16% of 1329
companies
in the Biotechnology industry
Industry Median: -6.91
vs TSHA: 484.87
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Taysha Gene Therapies 1-Year ROIIC % Related Terms
Taysha Gene Therapies 1-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Taysha Gene Therapies's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSHA vs KARD, GHRS, VIR: 1-Year ROIIC % Comparison
For the Biotechnology subindustry, Taysha Gene Therapies's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taysha Gene Therapies 1-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Taysha Gene Therapies's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Taysha Gene Therapies's 1-Year ROIIC % falls into.
Taysha Gene Therapies's 1-Year ROIIC % for the quarter that ended in Jun. 2026 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( -156.592 (Jun. 2026) - -89.166 (Jun. 2025) )
/
( 15.888 (Jun. 2026) - 29.794 (Jun. 2025) )
=
-67.426
/
-13.906
=
484.87%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Taysha Gene Therapies (TSHA) has a 1-Year ROIIC % of 484.87 as of Jun. 2026. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Taysha Gene Therapies and its competitors. According to the industry distribution chart, Taysha Gene Therapies ranks #144 out of 1329 companies in the Biotechnology industry, placing it in the top 10.8%.
Is Taysha Gene Therapies' 1-Year ROIIC % too high?
Taysha Gene Therapies' current 1-Year ROIIC % is 484.87. Based on the distribution chart, Taysha Gene Therapies ranks #144 out of 1329 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Taysha Gene Therapies has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Taysha Gene Therapies' 1-Year ROIIC % compare to KARD and GHRS?
According to the Biotechnology industry distribution chart, Taysha Gene Therapies ranks #144 out of 1329 companies for 1-Year ROIIC %. This places Taysha Gene Therapies in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year ROIIC % for a Biotechnology company?
A good 1-Year ROIIC % depends on the Biotechnology industry context. However, 1-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year ROIIC % mean?
A high 1-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Taysha Gene Therapies and its competitors. Taysha Gene Therapies's current 1-Year ROIIC % is 484.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taysha Gene Therapies stock overvalued right now?
Based on GuruFocus' analysis, Taysha Gene Therapies (TSHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.53, compared to a current price of $5.02 — trading 847.2% above its estimated fair value. The current 1-Year ROIIC % is 484.87. Taysha Gene Therapies' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year ROIIC % calculated?
1-Year ROIIC % is calculated from a company's financial statements. For Taysha Gene Therapies (TSHA), the current 1-Year ROIIC % is 484.87 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taysha Gene Therapies (TSHA) Overvalued in 2026?
Based on GuruFocus' analysis, Taysha Gene Therapies stock appears to be overvalued.
The current stock price of $5.02 is trading 847.2% above its estimated GF Value™ of $0.53.
GuruFocus considers Taysha Gene Therapies to be Significantly Overvalued.
Key valuation signals for TSHA:
1-Year ROIIC %: 484.87
GF Value™: $0.53 vs. price of $5.02 (847.2% above fair value)
No single metric tells the full story. See the TSHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
33GF Score
Get the complete analysis for TSHA
1-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSHA has been successfully added to your 
